Valeant’s Higher Bid Seals The Deal With Salix, Ending Endo’s Quest
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant raised its offer to buy the GI specialist from $158 to $173 per share in cash; Salix’s board of directors accepted the revised offer, ending a bid by Endo to buy the company.
You may also be interested in...
Pharming Regains Rights To Ruconest, Seizing More Control Over Its Destiny
The European specialty pharma will pay $60m upfront to Valeant to reacquire the rights to commercialize the hereditary angioedema treatment in North America.
Valeant’s Oral Relistor Poised To Face-Off Against AstraZeneca’s Movantik
FDA approval of the first oral form of Valeant’s mu-opioid receptor antagonist Relistor will pit the franchise against Movantik for the treatment of patients with opioid-induced constipation with non-cancer pain.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.